SOURCE-LINKED STUDY SUMMARY
Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial.
Abstract summarizedQuality not appraised
- What was studied
- A randomized, double-blind phase 2 substudy in adults with type 2 diabetes compared retatrutide with placebo and dulaglutide. Its primary outcome was total fat-mass change measured by body-composition scans over 36 weeks.
- Who / model studied
- 189 participants entered the body-composition substudy; 103 completed treatment and both scheduled scans.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- What the study found
- Fat mass fell 15·2–26·1% in the higher retatrutide groups versus 4·5% with placebo and 2·6% with dulaglutide. The lowest retatrutide group did not significantly differ from placebo. Lean-mass loss as a proportion of weight loss resembled other obesity treatments. Gastrointestinal events were most common; serious adverse events occurred in some groups, with no deaths.
- Limitations & context
- No author-stated limitations were available in the abstract. Only 103 of 189 participants completed treatment and paired scans.
Read summary source ↗ · Prepared 9/22/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1016/s2213-8587(25)00092-0